Mark W. Sherman
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mark W. Sherman
Informally, FDA appears open to trials that use cognition as the only primary endpoint rather than insisting that products also show benefit on the functional side.
Argos Therapeutics reports FDA support for its plan to continue its ADAPT trial of rocapuldencel-T for metastatic renal cell carcinoma despite a futility finding by the independent data monitoring committee.